CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735. CordenPharma provides large-scale ...

Viking Therapeutics (NasdaqCM:VKTX) experienced a share price increase of 10% last week, coinciding with the announcement of a multi-year manufacturing agreement with CordenPharma for its V2735 ...

The expansion will more than double the existing SPPS reactor capacity at CordenPharma Colorado by adding an additional 25,000 L of SPPS capacity – making it a total reactor capacity of >42,000 ...

CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735. CordenPharma provides large-scale ...

BASEL, Switzerland, March 5, 2025 /PRNewswire/ -- Following its 16 July 2024 announcement, CordenPharma is pleased to share significant progress on its growth initiatives with a >€1 billion ...

- CordenPharma amplía su plataforma de péptidos con la construcción de una nueva instalación por valor de más de 500 millones de euros en la región de Basilea (Suiza) ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and other drugs, the CDMO’s investment plan is paying off big time.

After earmarking a major chunk of change last year to bulk up in peptide production, European CDMO CordenPharma is putting its money where its mouth is. CordenPharma will spend half of a planned ...

CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, and large peptide manufacturing facilities across Europe and the US.